Hoth Therapeutics Inc (OQ:HOTH)

Mar 27, 2024 02:00 pm ET
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (No. 3
Mar 27, 2024 08:27 am ET
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program
Feb 26, 2024 07:11 am ET
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers
Feb 13, 2024 10:45 am ET
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
NEW YORK, Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO CEO and Investor Conference in New York, NY. 
Jan 18, 2024 07:20 am ET
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics
Dec 27, 2023 07:21 am ET
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.
Dec 05, 2023 07:33 am ET
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Hoth also recently completed its Pre-IND meeting with FDA in November.
Nov 14, 2023 07:37 am ET
Nov 10, 2023 07:00 am ET
Oct 05, 2023 10:03 am ET
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
The new wholly owned subsidiary will screen for rare disease therapeutics.
Oct 02, 2023 08:33 am ET
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
NEW YORK, Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023.
Sep 15, 2023 02:38 pm ET
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
NEW YORK, Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof). In addition, in a concurrent private placement, Hoth issued unregistered warrants to purchase up to 1,100,00
Sep 13, 2023 01:43 pm ET
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
NEW YORK, Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Hoth will issue unregistered warrants to purchase up to 1,100,000 shares of
Sep 13, 2023 08:16 am ET
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT.
Sep 11, 2023 10:04 am ET
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic
Jul 25, 2023 08:12 am ET
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
NEW YORK, July 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Jul 19, 2023 08:02 am ET
Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic
FDA Approved Trial Now Has Two Sites Approved with Additional Sites in Approval Process
Jun 06, 2023 08:02 am ET
May 12, 2023 08:38 am ET
Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge
Hoth to Concentrate on its Current Pipeline and Continue Phase 2 Clinical Study
May 01, 2023 12:27 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Apr 29, 2023 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEI
Hoth Therapeutics, Inc. (NASDAQ: HOTH) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of HOTH with Algorithm Sciences, Inc., whereby HOTH shareholders are expected to own...
Apr 28, 2023 01:03 pm ET
Moore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law Firm
NEW YORK, April 28, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Apr 28, 2023 09:17 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPPI, HOTH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Spectrum Pharmaceuticals, Inc....
Apr 27, 2023 04:41 pm ET
HOTH THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Hoth Therapeutics, Inc. - HOTH
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Hoth Therapeutics, Inc. (NasdaqCM: HOTH) with Algorithm Sciences, Inc. pursuant to which Hoth shareholders are currently anticipated to own approximately 14% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Apr 27, 2023 10:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH
NEW YORK, April 27, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Apr 26, 2023 11:07 am ET
HOTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Hoth Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Algorithm Sciences, Inc. is fair to Hoth shareholders. Upon completion of the proposed transaction, Hoth shareholders are expected to own approximately 14% of the combined company.
Apr 26, 2023 08:18 am ET
Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge
Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board
Mar 08, 2023 08:09 am ET
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
NEW YORK, March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and nec
Feb 16, 2023 07:35 am ET
Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity
Strengthens Measures to Safeguard Shareholder Interests through ShareIntel's Investigation and Due Diligence Services for Illegal Short Selling
Feb 08, 2023 07:43 am ET
Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ
HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and
Jan 03, 2023 03:38 pm ET
Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, Jan. 3, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced private placement of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $10 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company sold and issued 2,000,000 shares of common stock (or pre-fund
Dec 30, 2022 09:58 am ET
Thinking about buying stock in Mullen Automotive, Hoth Therapeutics, Futu Holdings, Shaw Communications, or Ardelyx?
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, HOTH, FUTU, SJR, and ARDX.
Dec 29, 2022 07:00 pm ET
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to purchase up to an aggregate of 2,500,000 shares of common stock, at a purchase price of $5.00 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the private placement are expected
Dec 29, 2022 09:58 am ET
Thinking about buying stock in Esports Entertainment, Ardelyx, Gaotu Techedu, Hoth Therapeutics, or IQIYI?
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, ARDX, GOTU, HOTH, and IQ.
Dec 01, 2022 09:45 am ET
Nov 09, 2022 11:38 am ET
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.
Oct 31, 2022 09:57 am ET
Oct 24, 2022 04:15 pm ET
Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022. Commencing with the opening of trading on The Nasdaq Capital Market on October 26, 2022, the company's common stock will trade on a post-split basis under the same trading symbol, "HOTH".
Sep 20, 2022 09:05 am ET
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke
TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S.
Sep 06, 2022 09:31 am ET
Thinking about buying stock in Applied DNA Sciences, Hoth Therapeutics, Peabody Energy, Eyenovia, or Nio?
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, HOTH, BTU, EYEN, and NIO.
Sep 06, 2022 08:21 am ET
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders
Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model
Aug 16, 2022 03:00 pm ET
Sidoti's August Micro-Cap Virtual Conference
NEW YORK, NY / ACCESSWIRE / August 16, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.
Aug 12, 2022 01:48 pm ET
Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today announced the company will be presenting at the Sidoti Investor Conference taking place on August 17-18, 2022.
Jul 12, 2022 10:26 am ET
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model
Chronic treatment with HT-ALZ (>5 weeks) demonstrated significant improvement in behavioral and cognitive function tests in an Alzheimer's disease (AD) mouse model supporting a positive therapeutic potential of HT-ALZ for treatment of AD
Jun 29, 2022 01:25 pm ET
Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
NEW YORK, June 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement (the "Additional Compliance Period").
Jun 24, 2022 08:35 am ET
Thinking about buying stock in Toughbuilt Industries, CytomX Therapeutics, Can Fite Biopharma, Hoth Therapeutics, or Bally's?
NEW YORK, June 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, CTMX, CANF, HOTH, and BALY.
Jun 21, 2022 12:30 pm ET
Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis
NEW YORK, June 21, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.
Jun 15, 2022 12:30 pm ET
Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022
NEW YORK, June 15, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the "Annual Meeting") was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting. No business other than the adjournment was conducted on June 15, 2022. The Annual Meeting to be held on June 23, 2022 will be held virtually at www.virtualshareholdermeeting.com/HOTH2022.
Jun 09, 2022 08:18 am ET
Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ
The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials
May 03, 2022 08:09 am ET
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort
The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints
Apr 19, 2022 10:29 am ET
Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury
HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury
Apr 14, 2022 01:02 pm ET
Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market
NEW YORK, April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additi
Apr 12, 2022 10:45 am ET
Thinking about buying stock in Lixte Biotechnology, Hoth Therapeutics, Ocugen, Bilibili, or Sunshine Biopharma?
NEW YORK, April 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LIXT, HOTH, OCGN, BILI, and SBFM.
Apr 12, 2022 08:17 am ET
Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference
Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease
Apr 11, 2022 11:31 pm ET
Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market
NEW YORK, April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,235,294 shares
Apr 11, 2022 04:21 pm ET
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering.
Apr 11, 2022 09:47 am ET
BioMed Leaders: Hoth Therapeutics, Nova Mentis Life Sciences, Tonix Pharmaceuticals, and MedAvail; Visionary CEOs Report Latest Advances in Novel Therapeutics for Autism, Cancer, and Fibromyalgia, and
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Hoth Therapeutics (NASDAQ: HOTH), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Tonix...
Apr 11, 2022 09:31 am ET
Thinking about buying stock in Hoth Therapeutics, Spectrum Pharmaceuticals, Datto Holding, Bilibili, or Hycroft Mining?
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, SPPI, MSP, BILI, and HYMC.
Apr 11, 2022 08:05 am ET
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells
Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours
Apr 01, 2022 08:02 am ET
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention
Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the Hoth Therapeutics Pipeline, including new proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease Therapeutic
Mar 22, 2022 09:48 am ET
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance
NEW YORK, March 22, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) on March 11, 2022. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting. Preclinical studies have demonstrated that HT-KIT induces apoptosis of neoplastic mast cells and reduces metastasis associated with aggressive mastocytosis.
Mar 11, 2022 07:00 am ET
Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis
NEW YORK, March 11, 2022 /PR Newswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) designated HT-KIT, a new molecular entity, as an Orphan Drug for the treatment of mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting. Preclinical studies have demonstrated that HT-KIT induces apoptosis of neoplastic mast cells and reduces metastasis associated with aggressive mastocytosis.
Feb 09, 2022 09:10 am ET
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.
Feb 07, 2022 07:02 am ET
Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference
NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California.
Jan 31, 2022 07:17 am ET
Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board.
Jan 07, 2022 08:31 am ET
Thinking about buying stock in Astra Space, Greenbox, Hoth Therapeutics, Ree Automotive, or Stryve Foods?
NEW YORK, Jan. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ASTR, GBOX, HOTH, REE, and SNAX.
Jan 05, 2022 09:55 am ET
Thinking about buying stock in Farmmi, Zosano Pharma, Hoth Therapeutics, Reliance Global, or United States Steel?
NEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FAMI, ZSAN, HOTH, RELI, and X.
Jan 04, 2022 08:31 am ET
Thinking about buying stock in Hoth Therapeutics, Agrify, Nine Energy Service, Nextier Oilfield Solutions, or Jaguar Health?
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, AGFY, NINE, NEX, and JAGX.
Jan 04, 2022 07:01 am ET
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
NEW YORK, Jan. 4, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ. The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease (AD).
Dec 21, 2021 06:59 am ET
Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Request to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocytosis.
Dec 08, 2021 07:00 am ET
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics ("Zylö") to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö.
Nov 30, 2021 07:00 am ET
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that enrollment and dosing has begun for the second cohort in its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema.
Nov 16, 2021 07:30 am ET
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University ("NC State") to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cancers.
Nov 08, 2021 07:38 am ET
Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT. HT-KIT is a new molecular entity (NME) morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (aggressive systemic mastocytosis (ASM), s
Oct 19, 2021 12:47 pm ET
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn's disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery in Glasgow.
Oct 12, 2021 10:00 am ET
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients
NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. 
Sep 22, 2021 07:00 am ET
Hoth Therapeutics, Inc.: Invitation to the Benzinga Healthcare Small Cap Conference
Detroit, Michigan--(Newsfile Corp. - September 22, 2021) - Hoth Therapeutics, Inc. (NASDAQ: HOTH) will be presenting at the Benzinga Healthcare Small Cap Conference taking place on September 29-30, 2021. We invite our shareholders and all interested parties to explore healthcare small cap investment opportunities through two days of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/healthcare/.
Sep 21, 2021 10:05 am ET
Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial
NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing patients with mild to moderate atopic dermatitis, also known as eczema.  There were no serious adverse events and no drug-related treatment-emergent adverse events observed during the administration of BioLexa in healthy subjects. Based on the recommendations of the SRC, Hoth has submitted to the H
Sep 08, 2021 08:02 am ET
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Aug 11, 2021 09:01 am ET
Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.
Aug 11, 2021 08:30 am ET
Thinking about buying stock in CohBar, Mogo, BioCryst Pharmaceuticals, Hoth Therapeutics, or Maravai Lifesciences?
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CWBR, MOGO, BCRX, HOTH, and MRVI.
Aug 02, 2021 08:15 am ET
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease
NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
Jul 13, 2021 08:15 am ET
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology. The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.
Jun 28, 2021 08:01 am ET
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Apr 13, 2021 08:00 am ET
Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD
Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on Thursday April 8th. This follows dozens of recent one-on-one briefings with Congressional staffers....
Mar 24, 2021 08:00 am ET
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing as...
Feb 25, 2021 08:55 am ET
Hoth Therapeutics Retains RedChip to Increase Investor Awareness
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts.
Feb 24, 2021 09:20 am ET
Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment
NEW YORK, Feb. 24, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer's disease.  Hoth also secured an exclusive license agreement with respect to the use of this drug for other indications.
Feb 23, 2021 07:02 am ET
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients
NEW YORK, Feb. 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for their HT-001 product. The Pre-IND meeting was completed through written responses provided by the FDA Division of Dermatology and Dentistry on February 22, 2021.
Feb 18, 2021 07:01 am ET
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis. Hoth executed an option agreement with Isoprene Pharmaceuticals, Inc. ("Isoprene") to investigate the potential for the HT-003 API as an IBD therapeutic. Isoprene is a University of Maryland, Baltimore New Venture Initiative start-up company.
Feb 17, 2021 07:00 am ET
Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor conference on February 24, 2021.
Feb 10, 2021 12:30 pm ET
Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv
NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 SARS-CoV-2 titled, "Transformations, Comparisons, Analysis of Down to Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein including the UK Variant B.I.I.7."
Feb 09, 2021 08:00 am ET
Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
Voltron Therapeutics, Inc. announced today it has initiated its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study will investigate an updated construct, based on initial testing as...
Feb 08, 2021 01:51 pm ET
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for HT-001 topical product to the U.S. Food and Drug Administration for initiating the first clinical trial. 
Feb 02, 2021 07:45 am ET
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications.
Jan 28, 2021 07:02 am ET
Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research
NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne. The 1-year agreement extension is based on positive results generated from the prior research agreement that support a therapeutic effect of HT-003 in key signaling pathways contributing to the development
Jan 27, 2021 07:31 am ET
Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("Hoth" or the "Company"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. to the Company's Scientific Advisory Board. 
Jan 20, 2021 07:38 am ET
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.
Jan 13, 2021 07:01 am ET
FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted to receive written responses only from FDA that are targeted for delivery on February 22, 2021.
Jan 11, 2021 07:02 am ET
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.
Jan 05, 2021 08:00 am ET
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to institutional investors.  Upon the closing of the financing, the Company expects to receive gross proceeds of approximately $5.0 million, not including any proceeds that may be received upon exercise of warrants. The closing of the financing is subject to customary closing conditions. 
Jan 04, 2021 07:01 am ET
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections
NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command (USAMRDC) for a new molecular entity (NME) developed by the Walter Reed Army Institute of Research with a novel antibacterial mechanism of action that targets multiple bacterial pathogens. 
Dec 31, 2020 07:01 am ET
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment
NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001  with Tergus Pharma for its novel cancer treatment drug, HT-001.
Dec 23, 2020 08:55 am ET
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer
Dec 21, 2020 07:30 am ET
Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Therapeutic options for CLE are limited to steroids (topical and oral), topical calcineurin inhibitors, and other immunomodulating therapies that could have adverse effects during long-term use. Zylö Therapeutics has developed a patented topical delivery system usin
Dec 10, 2020 09:11 am ET
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. 
Nov 16, 2020 11:29 am ET
Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit
Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020. Importantly, the...
Nov 03, 2020 08:25 am ET
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. 
Nov 02, 2020 09:16 am ET
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed. Hoth Therapeutics has cast a wide net to contribute to the fight against COVID-19 that includes: HT-002 peptide therapeutic targeted to treat symptoms associated with COVID-19, the On-the-Go SARS-CoV-2 Testing Device, and VaxCelerate SARS-CoV-2 vaccine.
Oct 20, 2020 10:30 am ET
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,793,525 related to novel 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers.  This patent is also the first of its kind, expiring on October 5, 2036.
Sep 22, 2020 06:30 pm ET
Sidoti Virtual Investor Conference
NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for Wednesday, September 23, 2020, the first day of its two-day Fall 2020 Virtual Investor Conference. The presentation schedule and related links for day two of the virtual event, Thursday, September 24, 2020, will be published shortly after the conclusion of Wednesday's session or can be found at www.sidoticonference.com/events (click Schedule).
Sep 16, 2020 09:40 am ET
Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization
Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The agreement partners Voltron with a...
Sep 15, 2020 08:30 am ET
Voltron Therapeutics, Inc. Announces Completion of First Small Animal Safety and Immunogenicity Study Assessing the Effect of Novel COVID-19 Vaccine, HaloVax™
Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study assessing the effect of novel Covid-19 vaccine HaloVax™. The vaccine construct was administered with...
Aug 31, 2020 05:00 pm ET
LD Micro -- 360 Companies Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 25, 2020 11:01 am ET
Laidlaw Venture Partners Hosts Panel Discussion “Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy”
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced that on Monday, August 24, 2020, it held a panel discussion titled “Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine...
Aug 10, 2020 05:05 pm ET
Hoth Therapeutics to Participate in LD Micro's Zooming with LD, August 11th 8 AM PDT
NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that the Company would be presenting at LD Micro's Zooming with LD on Tuesday, August 11th, 2020.
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Jul 31, 2020 09:08 am ET
Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological Diseases
NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up.
Jul 09, 2020 09:26 am ET
Voltron Therapeutics Retains Buenaventura Advisors, LLC to Explore Strategic Alternatives for its HaloVax™ Subsidiary
Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc.  HaloVax was...
Jul 08, 2020 08:30 am ET
Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19
Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targets...
Jun 30, 2020 09:08 am ET
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.
Jun 16, 2020 09:24 am ET
Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232
NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.
Jun 15, 2020 08:48 am ET
Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper
NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, has published a white paper detailing his mappings of the COVID-19 virus and its spike protein.
Jun 08, 2020 09:08 am ET
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions
NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAMBA Retinamides that Degrade MNKs for Treating Cancer".
Jun 03, 2020 08:00 am ET
Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline
NEW YORK, June 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as a COVID-19 vaccine and peptide therapeutic.
May 27, 2020 01:50 pm ET
Hoth Therapeutics Announces Closing of Public Offering of Common Stock
NEW YORK, May 27, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182 shares of its common stock, at a price to the public of $2.75 per share. The gross proceeds to Hoth from this offering are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Hoth.  In addition, Hoth has granted the underwriters a 45-day option to purchase up to an addi
May 22, 2020 08:00 am ET
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could potentially slow its transmission.  Dr. Peters is also a recent recipient of COVID-19 Rapid Research Funding sponsored by the Office of the Vice President for Research and Innovation and the C. Kenneth and Dianne Wrig
May 21, 2020 09:07 pm ET
Hoth Announces Pricing of Public Offering of Shares of Common Stock
NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Hoth. Gross proceeds f
May 21, 2020 04:01 pm ET
Hoth Announces Proposed Public Offering of Common Stock
NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to
May 20, 2020 08:00 am ET
Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.
May 18, 2020 08:00 am ET
Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment
NEW YORK, May 18, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previously executed sublicense agreement for the compound with Chelexa Biosciences, Inc.
May 05, 2020 09:40 am ET
Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.
NEW YORK, May 5, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö").
Apr 24, 2020 10:08 am ET
Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine
NEW YORK, April 24, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the v
Apr 24, 2020 09:43 am ET
Hoth Therapeutics, Inc., Voltron Therapeutics, Inc., & HaloVax Announce Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine
NEW YORK, April 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV).  Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation
Apr 23, 2020 09:42 am ET
REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
NEW YORK, April 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.  Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to [email protected].
Apr 22, 2020 08:07 am ET
Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate
NEW YORK, April 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.  Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to [email protected] .
Apr 21, 2020 10:18 am ET
Hoth Therapeutics Announces Top Line Preclinical Data from Cutaneous Lupus Erythematosus (CLE) Study
NEW YORK, April 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™. 
Apr 17, 2020 08:00 am ET
Hoth Therapeutics Announces Additions to its Board of Directors
NEW YORK, April 17, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors. The Company also announced the resignation of current board member, Mr. Anthony Hayes.
Apr 15, 2020 09:13 am ET
Dr. Mark Poznansky Co-Creator of VaxCelerate Appeared on MSNBC to Discuss COVID-19 Vaccines
NEW YORK, April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes last night to discuss COVID-19 vaccines and can be viewed from the following link https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view
Apr 09, 2020 08:00 am ET
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
NEW YORK, April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine. 
Apr 02, 2020 11:04 am ET
Hoth Update on HaloVax Partnership Vaccine to Fight COVID-19 with Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH)
NEW YORK, April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH). The goal of this partnership is to co-develop a new vaccine designed to protect patients at risk of novel coronavirus (COVID-19) infection, leveraging the Self-Assembling Vaccine (SAV) platform developed by the VIC and licensed exclusively to Voltron Therapeutics,
Mar 30, 2020 08:48 am ET
Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals, Inc. to License VNLG-152 for Treatment of Dermatological Diseases
NEW YORK, March 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full licensing rights of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up founded by Vincent Njar, the lead scientific inventor, which is developing novel small mo
Mar 27, 2020 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Allied Healthcare Products, Hoth Therapeutics, KB Home, or New York Mortgage Trust?
NEW YORK, March 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AHPI, HOTH, KBH, and NYMT.
Mar 27, 2020 08:00 am ET
HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection
NEW YORK, March 27, 2020 /PRNewswire/ --  HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ: HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.  Voltron Therapeutics, Inc. has acquired an exclusive license to this t
Mar 24, 2020 11:50 am ET
Emerging Markets Report: Hoth Therapeutics is Working on a Potential Coronavirus Vaccine (COVID-19)
Bright and early Monday morning, Hoth Therapeutics, Inc. (NASDAQ: HOTH) released news that the Company had entered into a joint venture agreement with its joint venture partner, Voltron Therapeutics, Inc., for the “Joint Development for a...
Mar 24, 2020 09:00 am ET
Hoth Announces Pricing of $5 Million Public Offering of Common Stock
NEW YORK, March 24, 2020 /PRNewswire/ --Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering of 1,449,275 shares of its common stock at a price to the public of $3.45 per share. Hoth expects to receive aggregate gross proceeds of approximately $5 million from the offering, before deducting the underwriting discount and estimated offering expenses. The offering is expected to close on or about March 26, 2020, subject to customary closing conditions.
Mar 23, 2020 04:52 pm ET
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics Inc. (Nasdaq: HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts"  underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Mar 23, 2020 09:00 am ET
Hoth Therapeutics Announces Agreement to Joint Development for a Self-Assembling Vaccine (SAV) for the Potential Prevention of the Coronavirus (COVID-19)
NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). 
Mar 23, 2020 08:18 am ET
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be named HaloVax) to commence preclinical studies for the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). 
Mar 19, 2020 10:05 am ET
Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss
NEW YORK, March 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne as well as gene therapy treatment for asthmatics, today announced results from a preclinical study demonstrating the potential effectiveness of WEG232, a topical treatment with specific substance P-receptor inhibitor for Erlotinib-induced facial dermatitis and hair loss in cancer patients.
Mar 16, 2020 08:40 am ET
Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share
NEW YORK, March 16, 2020 /PRNewswire/ -- Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth Therapeutics, Inc. (NASDAQ: HOTH). The report includes detailed information on Hoth Therapeutics' business model and recent developments. More detailed information can be found in Diamond Equity Research's September 2019 initiation report.
Jan 17, 2020 07:00 am ET
Emerging Markets Report:  A Very Big Deal
It doesn’t take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn’t take any research firm at all to suggest that an eczema related company like Hoth Therapeutics, Inc....
Jan 14, 2020 07:00 am ET
Emerging Markets Report: Acne, Eczema, and Asthma
The headline of our written offering today probably appears a little different from our regular titles. Typically we don’t lead with things that are so widely despised or feared. But when we are discussing biopharmaceutical company Hoth...
Dec 23, 2019 07:00 am ET
Emerging Markets Report: A Pretty Good Month
As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor communication. That has definitely not been the case for Hoth Therapeutics, Inc. (NASDAQ: HOTH) - a...
Dec 13, 2019 07:00 am ET
Emerging Markets Report - Hoth Therapeutics on the Fast Track Toward Delivering Eczema Therapy Products to Market
Nearly every person suffering from atopic dermatitis, more popularly known as “eczema,” knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter treatments are not always...
Dec 11, 2019 12:30 pm ET
Hoth Therapeutics, Inc. to Present at the Investor Summit on December 17th in Philadelphia
PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), will be presenting at this year's Investor Summit on December 17th in Philadelphia.
Nov 14, 2019 07:00 am ET
Hoth Therapeutics Initiates Preclinical Study Including Topical Form of Aprepitant for Dermatological Treatment Relating to Side Effects of Cancer Medication
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW), the initiation of  a preclinical study of Aprepitant for dermatological treatment relating to the side effects of cancer medication.
Nov 06, 2019 07:00 am ET
Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initiating a confirmatory study, related to their proprietary AEA-loaded Z-pods™ in the treatment of Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin.
Oct 16, 2019 11:53 am ET
Four Innovators Targeting Multi-Billion-Dollar Market Opportunities in: E-Commerce, Healthcare Augmented Reality, and Cannabis
Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, and conference presentation videos from some of the most talked about stocks today. The CEO Interviews and conference...
Oct 15, 2019 08:00 am ET
Hoth Therapeutics to Present at the Dawson James 5th Annual Small Cap Growth Conference
NEW YORK, Oct. 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Robb Knie, Chief Executive Officer, will be presenting at the Dawson James 5th Annual Small Cap Growth Conference which is being held October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida. 
Oct 14, 2019 08:00 am ET
Hoth Therapeutics Makes Donation to National Eczema Association in Sponsorship of "National Eczema Awareness Month"
NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has made a donation to the National Eczema Association in order to bring continued awareness to National Eczema Awareness Month this October. For more information or to donate, please click here.
Oct 08, 2019 08:30 am ET
Hoth Therapeutics Successfully Completes Phase I of In-Life Dose Escalation Study for Treating Eczema
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that they have completed Phase I of their In-Life dose escalation study. The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the first phase of the study being complete
Sep 25, 2019 12:32 pm ET
Wall Street Reporter presents: “NEXT SUPER STOCK - Live!” Investor Conference September 26, 2019
Wall Street Reporter will be hosting the “NEXT SUPER STOCK - Live!” livestream online-only investor conference on Thursday September 26, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to join:...
Sep 25, 2019 10:09 am ET
Emerging Markets Report: Looking Beyond Skin Deep
Today’s featured company Hoth Therapeutics, Inc. (NASDAQ: HOTH) makes its claim in the marketplace of Life Science ideas with an array of skin-related products that span a large portion of the dermalogical spectrum. As a relatively new issue...
Sep 24, 2019 08:00 am ET
Hoth Therapeutics, Inc. to Present at Diamond Equity Research Emerging Growth Invitational
NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Robb Knie, Chief Executive Officer, will be presenting at the Diamond Equity Research Emerging Growth Invitational in New York. 
Sep 18, 2019 10:51 am ET
New Ideas for Billion Dollar Markets: Emerging Leaders in Cannabis, Augmented Reality, and Healthcare
Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, and conference presentation video’s from some of the most talked about stocks today. While in totally different industries - what...
Sep 16, 2019 02:41 pm ET
Next Super Stock conference presenters: CYDY, MDCL, HOTH, NEXCF delivering results, and positioned for transformational growth in coming months
Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news updates from the company’s presenting at last month’s NEXT SUPER STOCK Live! investor conference....
Sep 06, 2019 08:00 am ET
Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference
NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Robb Knie, Chief Executive Officer, will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference in New York on September 10, 20919 and the RESI 2019 Conference in Boston on September 11, 2019.
Sep 04, 2019 08:00 am ET
Hoth Therapeutics, Inc. Issues Letter to Shareholders
NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders.
Aug 21, 2019 08:00 am ET
Hoth Therapeutics and Zylö Therapeutics Finalize Agreement
NEW YORK, Aug. 21, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today announced it has entered into a definitive partnership agreement with Zylö Therapeutics to develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin.
Jul 22, 2019 08:00 am ET
Hoth Therapeutics, Inc. Announces Positive Results from Pilot Study of BioLexa on Diabetic Skin Ulcers
NEW YORK, July 22, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of its Pilot Study of the BioLexa Platform's application on diabetic skin ulcers. 
Jul 15, 2019 08:00 am ET
Hoth Therapeutics, Inc. Expands Working Relationship with the George Washington University and Enters Exclusive License Option Agreement
NEW YORK, July 15, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into an exclusive license option agreement with the George Washington University (GW) pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer.
May 14, 2019 08:00 am ET
Hoth Therapeutics Signs Term Sheet with Zylö Therapeutics to Acquire a License and Jointly Develop a Product to Treat Lupus
NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that the company has signed a term sheet with Zylö Therapeutics Inc (Zylö) to co-develop a new treatment for patients suffering from Cutaneous Lupus Erythematosus (CLE).  CLE is a chronic autoimmune disease that affects the skin.
Apr 30, 2019 08:00 am ET
Hoth Therapeutics, Inc. to Present at the ThinkEquity Conference
NEW YORK, April 30, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that its Chief Executive Officer, Mr. Robb Knie will be presenting on May 2, 2019 at the ThinkEquity Conference.
Apr 18, 2019 08:00 am ET
Hoth Therapeutics, Inc. to Ring NASDAQ Closing Bell on April 22, 2019
NEW YORK, April 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders announced today its Chief Executive Officer Mr. Robb Knie will be joined by other members of the management team to ring the NASDAQ Closing Bell on Monday, April 22, 2019 to celebrate the Company's recent listing to the NASDAQ Capital Market. 
Apr 08, 2019 08:00 am ET
Hoth Therapeutics, Inc. Announces the Addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board
NEW YORK, April 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics.  The BioLexa Platform is a proprietary, pate
Mar 19, 2019 08:00 am ET
Hoth Therapeutics, Inc. Announces the Addition of Dr. Stefanie Johns, Ph.D. to the Company's Scientific Advisory Board
NEW YORK, March 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Stefanie Johns  to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics.  The BioLexa Platform is a proprietary, patented, drug compound platf
Mar 13, 2019 08:00 am ET
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
NEW YORK, March 13, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that Hoth Therapeutics, Inc. (Hoth) has entered into a Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc. 
Mar 11, 2019 08:00 am ET
Hoth Therapeutics Announces Dr. Jonathan Zippin as Senior Scientific Advisor
NEW YORK, March 11, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced Dr. Jonathan Zippin has been named Senior Scientific Advisor.  Dr.  Zippin will advise Hoth Therapeutics on the design, development and implementation of Hoth's proposed clinical study for atopic dermatitis in the pediatric population. 
Mar 04, 2019 07:00 am ET
Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center
NEW YORK, March 4, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it will begin its Pilot Study of BioLexa application on diabetic skin ulcers.  
Feb 25, 2019 08:00 am ET
Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board
Hoth Therapeutics, Inc.(NASDAQ:HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the addition of...
Feb 20, 2019 05:15 pm ET
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
Hoth Therapeutics Inc. (NASDAQ: HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the closing of its...
Feb 20, 2019 04:30 pm ET
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the...
Feb 20, 2019 03:30 pm ET
Hoth Therapeutics Inc. Announces Closing of Initial Public Offering
NEW YORK, Feb. 20, 2019 /PRNewswire/ -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share, resulting in aggregate gross proceeds of $7.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Hoth has
Feb 15, 2019 08:00 am ET
Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “HOTH”
Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.